-
Posted: November 24th, 2023, 3:00am GMT
Conditions: Liver Cancer
Interventions: Other: phenotyping
Sponsors: Inserm U955
Recruiting
-
Posted: November 20th, 2023, 3:00am GMT
Conditions: Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma; Determine Efficacy of Liver Transplantation After Neoadjuvant Systemic Therapy in Patients With Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Liver Transplant
Sponsors: Rutgers, The State University of New Jersey
Not yet recruiting
-
Posted: November 16th, 2023, 3:00am GMT
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy
Interventions: Drug: HAIC; Drug: Surufatinib; Drug: Tislelizumab
Sponsors: Wuhan Union Hospital, China
Not yet recruiting
-
Posted: November 10th, 2023, 3:00am GMT
Conditions: Gastric Cancer; Colon Cancer; Rectal Cancer; Breast Cancer; Lung Cancer; Esophagus Cancer; Cholangiocarcinoma; Pancreas Cancer
Interventions: Biological: CEA-targeted CAR-T cells; Biological: CEA-targeted CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; First Affiliated Hospital of Wannan Medical College
Recruiting
-
Posted: November 9th, 2023, 3:00am GMT
Conditions: Perihilar Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Not yet recruiting
-
Posted: November 3rd, 2023, 2:00am GMT
Conditions: Bile Duct Neoplasms; Jaundice, Obstructive; Bile Duct Diseases
Interventions: Diagnostic Test: cfDNA methylation detection
Sponsors: Air Force Military Medical University, China
Recruiting
-
Posted: October 31st, 2023, 2:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Drug: Rilvegostomig; Drug: Placebo; Drug: Capecitabine; Drug: Gemcitabine/Cisplatin; Drug: S-1 [Tegafur/Oteracil/gimeracil]
Sponsors: AstraZeneca
Not yet recruiting
-
Posted: October 30th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma, Hilar; Biliary Stricture; Hilar Cholangiocarcinoma; Klatskin Tumor; Biliary Disease; Bile Duct Diseases; Bile Duct Stenosis
Interventions: Device: Endoscopic nasobiliary duct cutting; Device: Bilateral plastic stent
Sponsors: First People's Hospital of Hangzhou
Recruiting
-
Posted: October 26th, 2023, 2:00am GMT
Conditions: Esophageal Cancer; Small Bowel Cancer; Gastroesophageal-junction Cancer; Gastric Cancer; Colorectal Cancer; Appendiceal Cancer; Biliary Cancer; Gall Bladder Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Oligoprogressive
Interventions: Device: Ablative local therapy
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Recruiting
-
Posted: October 24th, 2023, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Not yet recruiting
-
Posted: October 20th, 2023, 2:00am GMT
Conditions: Bile Duct Adenocarcinoma
Interventions: Drug: surufatinib plus cadonilimab
Sponsors: Zhejiang Cancer Hospital
Recruiting
-
Posted: October 13th, 2023, 2:00am GMT
Conditions: Advanced Pancreatic Cancer and Cholangiocarcinoma
Interventions: Drug: PRRT with 177Lu-EB-FAPI
Sponsors: Zhejiang University
Recruiting
-
Posted: October 13th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic
Interventions: Drug: Ivosidenib
Sponsors: Servier
Not yet recruiting
-
Posted: October 10th, 2023, 2:00am GMT
Conditions: Ampullary Cancer; Bile Duct Cancer; Pancreas Cancer; Duodenum Cancer
Interventions: Procedure: Modified Blumgart Anastomosis in LPD; Procedure: conventional Blumgart anastomosis in LPD
Sponsors: Affiliated Hospital of Guangdong Medical University
Enrolling by invitation
-
Posted: September 28th, 2023, 2:00am GMT
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Oligometastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Angiography; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tremelimumab; Procedure: Yttrium-90 Microsphere Radioembolization
Sponsors: Mayo Clinic
Not yet recruiting
-
Posted: September 27th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma Metastatic
Interventions: Drug: TT-00420 (tinengotinib)
Sponsors: TransThera Sciences (Nanjing), Inc.
Not yet recruiting
-
Posted: September 22nd, 2023, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cisplatin; Procedure: Computed Tomography; Biological: Durvalumab; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Procedure: Resection
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: September 21st, 2023, 2:00pm GMT
Conditions: Biliary Tract Tumor; Cholangiocarcinoma
Interventions: Other: Blood samples, tumor biopsy specimens will be collected
Sponsors: Zhejiang Cancer Hospital
Recruiting
-
Posted: September 21st, 2023, 2:00pm GMT
Conditions: Biliary Tract Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Zimberelimab; Drug: Quemliclustat
Sponsors: Nataliya Uboha; Arcus Biosciences, Inc.; Gilead Sciences; University of Wisconsin, Madison
Not yet recruiting
-
Posted: September 21st, 2023, 2:00pm GMT
Conditions: Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Pancreas Cancer; Non-small Cell Lung Cancer; Breast Cancer; Bile Duct Cancer
Interventions: Biological: CEA-targeted CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; Zhejiang University
Recruiting
-
Posted: September 14th, 2023, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Cisplatin; Procedure: Curative Surgery; Drug: Capecitabine
Sponsors: Gruppo Oncologico del Nord-Ovest
Recruiting
-
Posted: September 12th, 2023, 2:00pm GMT
Conditions: Combined Hepatocellular Cholangiocarcinoma
Interventions: Drug: gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Sponsors: Sichuan University
Not yet recruiting
-
Posted: September 8th, 2023, 2:00pm GMT
Conditions: Solid Tumor; Advanced Solid Tumor; Locally Advanced Solid Tumor; Colon Rectal Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer; Hepatocarcinoma; Breast Cancer; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Vulva Cancer; Melanoma
Sponsors: Centro di Riferimento Oncologico - Aviano
Recruiting
-
Posted: August 30th, 2023, 2:00pm GMT
Conditions: Borderline Resectable Carcinoma; Biliary Tract Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Surgical Resection
Sponsors: Georgetown University; AstraZeneca
Not yet recruiting
-
Posted: August 25th, 2023, 2:00pm GMT
Conditions: Gastric Cancer; Colon Cancer; Pancreas Cancer; Esophagus Cancer; Cholangiocarcinoma; Lung Cancer; Breast Cancer
Interventions: Biological: CEA CAR-T cells; Biological: CEA CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; The First Affiliated Hospital of Nanchang University
Recruiting
-
Posted: August 15th, 2023, 2:00pm GMT
Conditions: Klatskin Tumor; Cholangiocarcinoma; Biopsy, Fine-Needle; Endoscopic Retrograde Cholangiopancreatography
Interventions: Diagnostic Test: The sampling method selected in patients with suspected hilar cholangiocarcinoma
Sponsors: Qilu Hospital of Shandong University; First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital of Guangxi Medical University; LanZhou University; Sir Run Run Shaw Hospital; Wuhan Union Hospital, China
Recruiting
-
Posted: August 14th, 2023, 2:00pm GMT
Condition: HER2 Gene Mutation
Interventions: Combination Product: Injection of IAH0968+Gemcitabine+Cisplatin; Combination Product: Gemcitabine+Cisplatin
Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd.
Recruiting
-
Posted: August 7th, 2023, 2:00pm GMT
Condition: Cholangiocarcinoma Non-resectable
Interventions: Drug: Candonilimab; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: West China Hospital
Recruiting
-
Posted: August 2nd, 2023, 2:00pm GMT
Condition: Advanced Solid Tumors
Intervention: Drug: IMM2510
Sponsors: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Zhejiang Cancer Hospital; Fudan University
Recruiting
-
Posted: August 1st, 2023, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting
-
Posted: July 24th, 2023, 2:00pm GMT
Conditions: Pancreatic Cancer; Cholangiocarcinoma
Intervention: Diagnostic Test: [68Ga]Ga-FAPI-46 PET/CT
Sponsors: Amsterdam UMC, location VUmc; Dutch Cancer Society; Leiden University Medical Center
Recruiting
-
Posted: July 24th, 2023, 2:00pm GMT
Conditions: Metastatic Malignant Neoplasm
Interventions: Drug: NPX267
Sponsors: NextPoint Therapeutics, Inc.
Recruiting
-
Posted: July 17th, 2023, 2:00pm GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Tinengotinib 8 mg; Drug: Tinengotinib 10 mg; Drug: Physician's Choice
Sponsors: TransThera Sciences (Nanjing), Inc.
Not yet recruiting
-
Posted: July 5th, 2023, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HMPL-453; Drug: Rabeprazole
Sponsors: Hutchmed
Completed
-
Posted: June 27th, 2023, 2:00pm GMT
Conditions: IDH1-mutant Cholangiocarcinoma
Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier
Recruiting
-
Posted: June 27th, 2023, 2:00pm GMT
Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases
Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training
Sponsors: H. Lee Moffitt Cancer Center and Research Institute
Recruiting
-
Posted: June 22nd, 2023, 2:00pm GMT
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment
Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital
Recruiting
-
Posted: June 22nd, 2023, 2:00pm GMT
Condition: Bile Duct Cancer
Intervention: Drug: envolizumab , sovalteinib
Sponsor: Zhejiang Cancer Hospital
Not yet recruiting
-
Posted: June 9th, 2023, 2:00pm GMT
Conditions: Biliary Tract Diseases; Gallbladder Cancer; Extrahepatic Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Biliary Tract Neoplasms; Gall Stone
Intervention: Other: no interventions
Sponsor: RenJi Hospital
Not yet recruiting
-
Posted: May 25th, 2023, 2:00pm GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Ivosidenib Oral Tablet
Sponsors: Servier Affaires Médicales
Recruiting
-
Posted: May 25th, 2023, 2:00pm GMT
Condition: Perihilar Cholangiocarcinoma
Intervention: Device: Intrahepatic biliary stent with retrieval string
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting
-
Posted: May 24th, 2023, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: GNS561 + Trametinib
Sponsor: Genfit
Not yet recruiting
-
Posted: May 24th, 2023, 2:00pm GMT
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer; Non Small Cell Lung Cancer
Interventions: Biological: WM-A1-3389; Biological: Pembrolizumab
Sponsors: Wellmarker Bio; Merck Sharp & Dohme LLC
Not yet recruiting
-
Posted: May 15th, 2023, 2:00pm GMT
Conditions: Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Renal Cell Carcinoma; Bladder Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; Colorectal Cancer; Anal Cancer; Hepatocellular Carcinoma; Bile Duct Cancer
Interventions: Drug: AI-061
Sponsors: OncoC4, Inc.; OncoC4 AU Pty Ltd; Avance Clinical
Recruiting
-
Posted: May 9th, 2023, 2:00pm GMT
Conditions: Biliary Cancer; Bile Duct Cancer; Cancer of the Bile Duct
Interventions: Drug: oxaliplatin; Drug: capecitabine; Biological: Keytruda; Biological: CDX-1140
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: May 8th, 2023, 2:00pm GMT
Conditions: Breast Cancer Metastatic; Pancreatic Cancer; NSCLC, Metastatic; Synovial Sarcoma; Colon Cancer; Metastatic Colon Cancer; Melanoma Recurrent; Metastatic Skin Cancer; Melanoma Stage IV; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Cholangiocarcinoma; Ovarian Cancer; Metastatic Melanoma; Hepatocellular Carcinoma
Interventions: Drug: ST316
Sponsors: Sapience Therapeutics
Recruiting
-
Posted: April 28th, 2023, 2:00pm GMT
Condition: Advanced Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Cryoablation; Drug: Sintilimab; Drug: Lenvatinib
Sponsor: Fudan University
Recruiting
-
Posted: April 21st, 2023, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin; Drug: Gemcitabine and cisplatin
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor Hospital of Xinjiang Medical University
Recruiting
-
Posted: April 17th, 2023, 2:00pm GMT
Conditions: Cholangiocarcinoma With IDH1 Mutation; Solid Tumors With IDH1 Mutation
Intervention: Drug: AB-218 capsule
Sponsor: AnHeart Therapeutics Inc.
Not yet recruiting
-
Posted: April 10th, 2023, 2:00pm GMT
Conditions: Advanced Solid Tumor; Advanced Lung Cancer; Advanced Gastric Carcinoma; Advanced Cholangiocarcinoma
Intervention: Drug: IMM2902
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Recruiting
-
Posted: March 30th, 2023, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Solid Neoplasm; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: RNA Transcription Modulator AU-409
Sponsors: University of Southern California; National Cancer Institute (NCI); Auransa, Inc.
Recruiting
-
Posted: March 29th, 2023, 2:00pm GMT
Conditions: Non-small Cell Lung Cancer; Gastric Cancer; Head and Neck Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Bladder Urothelial Carcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Renal Cell Carcinoma; Cholangiocarcinoma; Pancreatic Cancer; Other Solid Tumors
Interventions: Drug: CDX-585
Sponsors: Celldex Therapeutics
Recruiting
-
Posted: March 23rd, 2023, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cadonilimab+Gem/Cis
Sponsors: Shen Feng
Active, not recruiting
-
Posted: March 16th, 2023, 2:00pm GMT
Conditions: Biliary Tract Cancer
Interventions: Biological: Durvalumab; Drug: Gemcitabine monotherapy; Drug: Gemcitabine + cisplatin; Drug: Gemcitabine + oxaliplatin; Drug: Gemcitabine + carboplatin; Drug: Gemcitabine + cisplatin + S-1; Drug: Gemcitabine + S-1; Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel
Sponsors: AstraZeneca
Recruiting
-
Posted: March 9th, 2023, 3:00pm GMT
Condition: Malignancy
Intervention: Drug: Al18F-PSMA-BCH PET/CT
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
-
Posted: March 1st, 2023, 3:00pm GMT
Condition: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Intervention: Drug: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
Sponsor: Yonsei University
Not yet recruiting
-
Posted: March 1st, 2023, 3:00pm GMT
Conditions: Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention: Other: No interventions
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting
-
Posted: February 24th, 2023, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Procedure: No intervention
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Recruiting
-
Posted: February 21st, 2023, 3:00pm GMT
Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Camrelizumab; Drug: Gemcitabine Injection; Drug: Cisplatin injection; Drug: Cisplatin-Eluting Beads; Procedure: D-TACE
Sponsors: Hua Li
Recruiting
-
Posted: February 17th, 2023, 3:00pm GMT
Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG462
Sponsors: Tango Therapeutics, Inc.
Recruiting
-
Posted: February 14th, 2023, 3:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement
Interventions: Drug: TAS-120
Sponsors: Taiho Oncology, Inc.
Recruiting
-
Posted: February 13th, 2023, 3:00pm GMT
Conditions: Hepatobiliary Cancer; Liver Cancer; Cholangiocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: Zimberelimab; Drug: Domvanalimab
Sponsors: University of Texas Southwestern Medical Center; Arcus Biosciences, Inc.; Cancer Prevention Research Institute of Texas
Recruiting
-
Posted: February 10th, 2023, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Diagnostic Test: No interventions.
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
-
Posted: February 8th, 2023, 3:00pm GMT
Conditions: Cholestasis; Icterus; Cholangiocarcinoma; Pancreatic Neoplasms; Liver Metastasis Colon Cancer
Intervention: Other: Biospecimen sampling
Sponsors: Nicole Hildebrand; RWTH Aachen University
Recruiting
-
Posted: February 6th, 2023, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Metastatic Colon Cancer; Metastatic Cancer; Metastatic Gastric Cancer; Primary Liver Cancer; Metastatic Pancreatic Cancer
Intervention: Procedure: Embolization
Sponsor: IRCCS San Raffaele
Recruiting
-
Posted: January 31st, 2023, 3:00pm GMT
Condition: Bile Duct Cancer
Intervention:
Sponsor: Power Life Sciences Inc.
Not yet recruiting
-
Posted: January 12th, 2023, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma; Cholangiocarcinoma, Perihilar; Intrahepatic Cholangiocarcinoma; Metastasis to Liver; Gallbladder Carcinoma
Intervention: Other: ADBoard
Sponsors: Charite University, Berlin, Germany; German Research Center for Artificial Intelligence
Not yet recruiting
-
Posted: January 10th, 2023, 3:00pm GMT
Conditions: Hilar Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Common Bile Duct Neoplasms; Cholangiocarcinoma; Adenocarcinoma
Interventions: Procedure: Endoscopic Ultrasound registration
Sponsors: Erasmus Medical Center
Recruiting
-
Posted: December 19th, 2022, 3:00pm GMT
Conditions: Bile Duct Cancer; Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Metastatic Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab; Radiation: Yttrium-90
Sponsors: Beth Israel Deaconess Medical Center; AstraZeneca; Sirtex Medical; Dana-Farber Cancer Institute
Recruiting
-
Posted: December 8th, 2022, 3:00pm GMT
Conditions: Gastrointestinal Cancers; Cholangiocarcinoma; Gastric Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: [18F]FAPI-74 PET/CT
Sponsors: SOFIE
Recruiting
-
Posted: November 14th, 2022, 3:00pm GMT
Conditions: Biliary Tract Neoplasms
Interventions: Drug: Futibatinib; Drug: Ivosidenib; Drug: Zanidatamab; Drug: Trastuzumab; Drug: Neratinib; Drug: Encorafenib; Drug: Binimetinib; Drug: Niraparib; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: UNICANCER; Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; National Cancer Institute, France; Cancer Research UK; Taiho Oncology, Inc.; Servier; Zymeworks Inc.; Accord Healthcare, Inc.; Pierre Fabre Medicament; GlaxoSmithKline Research & Development Limited
Not yet recruiting
-
Posted: November 1st, 2022, 2:00am GMT
Conditions: Cholangiocarcinoma; Bile Duct Neoplasms
Interventions: Procedure: Single-operator cholangioscopy
Sponsors: Soonchunhyang University Hospital
Recruiting
-
Posted: October 26th, 2022, 2:00pm GMT
Conditions: Biliary Obstruction; Pancreas Neoplasm; Distal Cholangiocarcinoma
Intervention: Device: EUS-CDS
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); VU University of Amsterdam
Recruiting
-
Posted: October 6th, 2022, 2:00pm GMT
Conditions: Ovarian Cancer; Cholangiocarcinoma Recurrent; Mesothelioma, Malignant
Interventions: Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Sponsors: Verismo Therapeutics
Recruiting
-
Posted: October 4th, 2022, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation
Intervention: Drug: Pemigatinib
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Incyte Biosciences International Sàrl
Recruiting
-
Posted: October 3rd, 2022, 2:00pm GMT
Conditions: Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma Multiforme; Cholangiocarcinoma; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Epithelial Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Soft Tissue Sarcoma
Intervention: Drug: 89Zr-DFO-girentuximab
Sponsor: Telix International Pty Ltd
Recruiting
-
Posted: October 3rd, 2022, 2:00pm GMT
Conditions: Recurrent Biliary Tract Carcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Carcinoma; Unresectable Distal Bile Duct Adenocarcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Binimetinib; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Procedure: Echocardiography; Drug: Fluorouracil; Drug: Leucovorin Calcium; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Drug: Oxaliplatin
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: October 3rd, 2022, 2:00am GMT
Conditions: Perihilar Cholangiocarcinoma
Interventions: Procedure: Endoluminal radiofrequency ablation; Procedure: Endoscopic biliary stenting
Sponsors: Clinical Hospital Colentina; Carol Davila University of Medicine and Pharmacy; Universitatea din Bucuresti
Recruiting
-
Posted: September 28th, 2022, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Tislelizumab combined with GEMOX (GOT) regimen
Sponsors: Zhejiang Cancer Hospital
Recruiting
-
Posted: September 22nd, 2022, 2:00pm GMT
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Photosensitizer; Procedure: Radiofrequency ablation (RFA)
Sponsors: University of Leipzig; Zentrum für Klinische Studien Leipzig
Recruiting
-
Posted: August 25th, 2022, 2:00pm GMT
Conditions: Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Infigratinib Phosphate; Drug: Nab-paclitaxel
Sponsors: Emory University; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: August 22nd, 2022, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver Cancer
Interventions: Drug: Infigratinib; Drug: Atezolizumab; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Helsinn Healthcare
Not yet recruiting
-
Posted: August 16th, 2022, 2:00pm GMT
Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Intervention: Drug: ABM-1310
Sponsor: ABM Therapeutics Shanghai Company Limited
Recruiting
-
Posted: August 12th, 2022, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Ablation; Hepatitis C
Interventions: Procedure: Ablation therapy
Sponsors: Rigshospitalet, Denmark
Completed
-
Posted: August 11th, 2022, 2:00pm GMT
Conditions: Hepatobiliary Cancer; Pancreatic Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Ampullary Cancer; Pancreatic Carcinoma
Intervention: Diagnostic Test: ctDNA Blood Collection
Sponsor: University of California, Irvine
Recruiting
-
Posted: July 18th, 2022, 2:00pm GMT
Conditions: Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic Cancer
Intervention:
Sponsors: Travera Inc; xCures
Recruiting
-
Posted: July 11th, 2022, 2:00pm GMT
Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Ovarian Adenocarcinoma; Pancreatic Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Non Small Cell Lung Cancer
Interventions: Biological: TC-510; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsor: TCR2 Therapeutics
Recruiting
-
Posted: July 7th, 2022, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Sarcopenia
Interventions: Diagnostic Test: Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
Sponsors: First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University; Eastern Hepatobiliary Surgery Hospital; Qilu Hospital of Shandong University
Enrolling by invitation
-
Posted: July 5th, 2022, 2:00am GMT
Conditions: Liver Cancer; Sarcopenia
Interventions: Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
Sponsors: First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University; Eastern Hepatobiliary Surgery Hospital; Qilu Hospital of Shandong University
Enrolling by invitation
-
Posted: June 27th, 2022, 2:00pm GMT
Conditions: Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Melanoma (Skin); Soft Tissue Sarcoma; Head and Neck Squamous Cell Carcinoma; Cholangiocarcinoma
Interventions: Drug: [Ga-68]-PNT6555; Drug: [Lu-177]-PNT6555
Sponsors: POINT Biopharma
Active, not recruiting
-
Posted: June 24th, 2022, 2:00pm GMT
Condition: Perihilar Cholangiocarcinoma
Intervention: Drug: PD-1antibody plus GEMOX
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
-
Posted: June 16th, 2022, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsors: Inova Health Care Services
Not yet recruiting
-
Posted: June 9th, 2022, 2:00am GMT
Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer
Interventions: Drug: ARB202
Sponsors: Arbele Pty Ltd
Recruiting
-
Posted: June 2nd, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Binkui Li
Recruiting
-
Posted: April 14th, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsor: Thomas Jefferson University
Recruiting
-
Posted: April 13th, 2022, 2:00pm GMT
Conditions: Solid Tumors
Interventions: Drug: Bemarituzumab
Sponsors: Amgen
Recruiting
-
Posted: April 6th, 2022, 2:00am GMT
Conditions: CNS Cancer; Head and Neck Cancer; GI Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; Breast Cancer
Interventions: Radiation: Pencil Beam Scanning Proton Therapy
Sponsors: The New York Proton Center
Recruiting
-
Posted: March 23rd, 2022, 2:00pm GMT
Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Intervention: Biological: Neoantigen specific TCR-T cell drug product
Sponsor: Alaunos Therapeutics
Recruiting
-
Posted: March 23rd, 2022, 2:00pm GMT
Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Interventions: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Recruiting
-
Posted: March 18th, 2022, 2:00pm GMT
Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsors: National Cancer Institute (NCI)
Recruiting